Skip to content

Overview

title: GLP-1 Receptor Agonists description: GLP-1 receptor agonist peptides — comprehensive research database on semaglutide, tirzepatide, retatrutide, and incretin-based metabolic research agents. date: 2026-07-25 ---GLP-1 Receptor Agonists

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of therapeutic peptides developed for metabolic research, including glucose homeostasis, body weight regulation, and energy metabolism. These compounds mimic the action of endogenous incretin hormones.

Overview

GLP-1 receptor agonists bind to and activate the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor expressed in the pancreas, brain, gastrointestinal tract, and peripheral tissues. Activation of GLP-1R stimulates glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes satiety.

The category includes three main peptide-based compounds:

Compound Class Primary Targets Distinctive Feature
Tirzepatide Dual agonist GIP, GLP-1 First-in-class GIP/GLP-1 dual agonist
Retatrutide Triple agonist GIP, GLP-1, Glucagon Triple receptor activation
Semaglutide Selective agonist GLP-1 Long-acting GLP-1 analogue

🔬 Mechanism of Action

Endogenous GLP-1 is secreted by intestinal L-cells in response to nutrient ingestion. It acts on the GLP-1 receptor to produce the following effects:

  • Pancreatic β-cells: Glucose-dependent insulin secretion
  • Pancreatic α-cells: Suppression of glucagon secretion
  • Stomach: Slowed gastric emptying
  • Brain: Increased satiety, reduced appetite
  • Adipose tissue: Enhanced lipolysis and energy expenditure
  • Heart: Cardioprotective effects

Receptor Binding Affinities

Compound GLP-1R EC50 GIPR EC50 GCGR EC50
Tirzepatide 0.06 nM 0.29 nM —
Retatrutide 0.09 nM 0.12 nM 0.26 nM
Semaglutide 0.04 nM — —

📊 Pharmacological Comparison

Parameter Tirzepatide Retatrutide Semaglutide
Half-life ~5 days ~6 days ~7 days (oral: ~1 week)
Route Subcutaneous (weekly) Subcutaneous (weekly) Subcutaneous (weekly) / Oral (daily)
Bioavailability ~80% (SC) ~75% (SC) ~89% (SC) / ~1% (oral)
Molecular Weight 4813.5 Da 4840.6 Da 4113.6 Da
Peak Concentration 8–24 h 12–24 h 12–24 h (SC)
Metabolic Clearance Proteolytic degradation Proteolytic degradation Proteolytic degradation

🔬 Research Evidence Summary

Preclinical Research

  • Tirzepatide: Demonstrated superior weight loss and glycemic control versus selective GLP-1R agonists in rodent models. Dual GIP agonism enhanced energy expenditure.
  • Retatrutide: Showed additive effects of triple agonism on body weight reduction and glucose tolerance in diet-induced obese mice.
  • Semaglutide: Established dose-dependent reductions in HbA1c and body weight in multiple preclinical models.

Published Research

  • SURPASS trials (Tirzepatide): Published studies demonstrated HbA1c reductions of 1.8–2.4% and weight loss of 7–15% depending on dose.
  • TRIUMPH trials (Retatrutide): Published data showed up to 17.5% weight loss at 48 weeks (12 mg dose).
  • STEP trials (Semaglutide): Published studies demonstrated 14.9% mean body weight reduction with 2.4 mg weekly dose.

🧪 Dosing Reference

Compound Typical Research Dose Reconstitution Storage
Tirzepatide 0.25–2.0 mg (SC weekly) Bacteriostatic water 2–8°C after reconstitution
Retatrutide 0.25–1.2 mg (SC weekly) Bacteriostatic water 2–8°C after reconstitution
Semaglutide 0.25–2.4 mg (SC weekly) Bacteriostatic water 2–8°C after reconstitution

⚗️ Physicochemical Properties

Property Tirzepatide Retatrutide Semaglutide
Solubility Water-soluble Water-soluble Water-soluble
logP ~4.8 ~4.9 ~4.5
pKa ~4.2 ~4.3 ~4.1
Isoelectric Point ~5.0 ~4.9 ~4.8

📚 Selected References

  1. Coskun T, et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Diabetes. DOI: 10.2337/db18-0027
  2. Jastreboff AM, et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity management. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
  3. Marso SP, et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. DOI: 10.1056/NEJMoa1607141
  4. Frias JP, et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. The Lancet. DOI: 10.1016/S0140-6736(21)01324-6
  5. Wilding JPH, et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. DOI: 10.1056/NEJMoa2032183